



A nonprofit independent licensee of the Blue Cross Blue Shield Association

Medication Assurance Program

If you are enrolled in a commercial health benefit plan provided by or administered by Excellus BlueCross BlueShield where the Medication Assurance Program benefit applies:

The following drugs were preliminarily approved through the accelerated approval pathway by the U.S. Food and Drug Association (FDA). At this time, these drugs have unconfirmed clinical benefit and **will not be covered under prescription drug benefits or medical benefits**. Drug manufacturers of the drugs listed below are required to conduct clinical studies to prove clinical benefit in order to achieve traditional/final FDA approval. These drugs will continue to be monitored and remain uncovered until clinical benefits are proven and confirmed by criteria set forth by the FDA.

- AMONDYS 45*
- AMTAGVI*
- ARIKAYCE
- BELEODAQ*
- BIZENGRI*
- COLUMVI*
- DANYELZA*
- ELREXFIO*
- EPKINLY*
- EXONDYS 51*
- FOLOTYN*
- IMDELLTRA*
- IQIRVO
- JAYPIRCA
- KEBILIDI*
- LIVDELZI
- LUNSUMIO*
- LYTGOBI
- MONJUVI*
- NORTHERA
- OCALIVA
- OJEMDA
- OXBRYTA
- PRALATREXATE*
- QALSODY*
- REZDIFFRA
- SKYSONA*
- TALVEY*
- TAZVERIK
- TECELRA*
- TECVAYLI*
- VILTEPSO*
- VONJO
- VOXZOGO
- VYONDYS 53*
- ZEPZELCA*
- ZIIHERA*
- ZYNLONTA*
- ZYNYZ*

If you have questions regarding your drug coverage, please contact customer care at the number on the back of your card.

*Medical benefit drug

Updated 2/19/2025